视网膜疾病治疗市场规模、份额和成长分析（按疾病、疾病类型、治疗技术、给药途径、最终用户和地区划分）－2026-2033年产业预测

全球视网膜疾病治疗市场规模预计在 2024 年达到 128.6 亿美元，从 2025 年的 140.2 亿美元增长到 2033 年的 279.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 9%。

全球视网膜疾病盛行率呈上升趋势，影响超过2.53亿人，对医疗保健系统造成沉重的经济负担。人口老化，尤其是50岁及以上人口数量的增长（他们占视力障碍患者的81%），预计将进一步推动眼科护理需求。糖尿病视网膜病变等疾病发生率的上升与糖尿病发生率的上升密切相关，尤其是在新兴市场。视网膜疾病管理专家的日益增加预计将促进市场成长。此外，各地区加强昂贵视网膜治疗的报销政策预计将进一步推动市场扩张，并为该产业在视网膜疾病治疗方案方面取得重大进展奠定基础。

推动全球视网膜疾病药物市场发展的因素

眼科疾病发生率的不断上升，尤其是在已开发国家，正显着推动全球视网膜治疗市场的发展。糖尿病视网膜病变等疾病影响全球数百万患者，凸显了有效治疗方法的紧迫感。此外，预计老龄化黄斑部病变（AMD）病例的增加也将促进市场扩张。加强眼科疾病健康教育的努力，尤其是在发展中地区，正在推动早期疗育和治疗，从而刺激对视网膜疾病治疗的需求。人们对这类治疗方案日益增长的认识和需求，将显着促进市场成长。

限制全球视网膜疾病药物市场的因素

全球视网膜疾病治疗市场的扩张面临许多重大挑战。视网膜治疗的高昂费用是一大障碍，而患者往往担忧短期副作用和潜在的长期併发症，例如雷射眼科手术等治疗后可能发生的感染疾病和发炎。此外，诸如气动视网膜固定术等手术技术也存在风险，例如意外巩膜穿孔，这可能会影响患者的选择，并进一步阻碍市场成长。除了这些问题之外，开发中国家医疗基础设施的不足也为全球视网膜疾病治疗的发展带来了额外的障碍。

视网膜疾病治疗市场的全球趋势

由于先进技术的涌现，特别是基因治疗领域的发展，全球视网膜疾病治疗市场正经历显着成长。视网膜基因治疗等创新技术正在革新遗传性视网膜疾病（如莱伯氏先天性黑朦症）的治疗，例如，Luxturna等治疗方法展现出恢復患者视力的潜力。视网膜治疗领域正迅速发展，目前有许多基于重组病毒的基因疗法正在进行临床试验。这一趋势凸显了人们对个人化医疗和标靶治疗日益增长的关注，随着新型治疗方法获得监管部门核准并惠及更多患者，预计市场将大幅扩张。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球视网膜疾病治疗市场规模（按疾病类型和复合年增长率划分）（2025-2031 年）

• 老龄化黄斑部病变
• 糖尿病视网膜病变
• 视网膜剥离
• 视网膜母细胞瘤
• 黄斑皱褶
• 黄斑裂孔
• 漂浮物

全球视网膜疾病治疗市场规模（按疾病类型和复合年增长率划分）（2025-2031 年）

• 遗传
• 与老龄化相关的

全球视网膜疾病药物市场规模（依治疗技术及复合年增长率划分）（2025-2031 年）

• 雷射
• 冷冻疗法
• 植入
• 压迫疗法
• 气动视网膜固定术
• 巩膜扣带术
• 玻璃体切除手术

全球视网膜疾病治疗市场规模（依给药途径及复合年增长率划分）（2025-2031 年）

• 口服
• 局部用药
• 玻璃体内注射
• 其他的

全球视网膜疾病药物市场规模（依最终用户划分）及复合年增长率（2025-2031 年）

• 医院
• 门诊手术中心
• 家庭医疗保健
• 其他的

全球视网膜疾病药物市场规模（依分销管道划分）及复合年增长率（2025-2031 年）

• 直接竞标
• 医院药房
• 零售药房
• 网路药房
• 其他的

全球视网膜疾病治疗市场规模及复合年增长率（2025-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2023 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2023）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Regeneron Pharmaceuticals, Inc.（USA）
• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• Allergan（part of AbbVie）（USA）
• Bayer AG（Germany）
• Oculis（Switzerland）
• REGENXBIO Inc.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Apellis Pharmaceuticals, Inc.（USA）
• Iveric Bio, Inc.（USA）（Acquired by Astellas）
• Annexon Biosciences（USA）
• Hemera Biosciences（USA）（Acquired by Roche）
• Gyroscope Therapeutics（UK）（Acquired by Novartis）
• Graybug Vision, Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Ocuphire Pharma, Inc.（USA）
• Lineage Cell Therapeutics, Inc.（USA）
• Ocugen, Inc.（USA）

结论与建议

Global Retinal Disease Therapeutics Market size was valued at USD 12.86 Billion in 2024 and is poised to grow from USD 14.02 Billion in 2025 to USD 27.93 Billion by 2033, growing at a CAGR of 9% during the forecast period (2026-2033).

The prevalence of retinal disorders is escalating globally, impacting over 253 million individuals and exerting considerable financial pressure on healthcare systems. The aging population, particularly those over 50 who represent 81 percent of vision-impaired patients, is set to intensify demands on ophthalmic care. Rising rates of conditions like diabetic retinopathy are linked to the growing incidence of diabetes, particularly in emerging markets. As the availability of specialized professionals in retinal disease management increases, market growth is anticipated. Additionally, enhanced reimbursement policies for costly retinal treatments in various regions are expected to further stimulate market expansion, positioning the industry for significant advancements in therapeutic solutions for retinal diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Disease Therapeutics Market Segments Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Disease Therapeutics Market

The increasing incidence of eye-related diseases, especially in developed nations, is significantly propelling the global market for retinal therapeutics. A considerable number of individuals are affected by conditions such as diabetic retinopathy, with millions suffering globally, highlighting the urgent need for effective treatments. Moreover, the anticipated rise in cases of age-related macular degeneration (AMD) will further contribute to market expansion. Efforts to enhance health education around eye disorders are encouraging early intervention and treatment, particularly in developing regions, thereby driving demand for retinal disease treatments. This growing awareness and need for therapeutic solutions will bolster market growth significantly.

Restraints in the Global Retinal Disease Therapeutics Market

The expansion of the global retinal disease therapeutics market faces several significant challenges. High costs associated with retinal treatment therapies pose a major barrier, while patients often express concerns regarding short-term side effects and potential long-term complications, including infections and inflammation that may occur after procedures like laser eye surgery. Moreover, surgical methods such as pneumatic retinopexy carry risks, including unintentional scleral perforation, which can influence patient choices and further inhibit market growth. Compounding these issues, inadequate healthcare infrastructure in developing countries creates additional obstacles for the advancement of retinal disease therapies on a global scale.

Market Trends of the Global Retinal Disease Therapeutics Market

The Global Retinal Disease Therapeutics market is experiencing significant growth driven by the emergence of advanced technologies, particularly in gene therapy. Innovations such as retinal gene therapy are revolutionizing treatments for inherited retinal disorders like Leber's congenital amaurosis, with therapies like Luxturna showcasing the potential to restore vision in affected patients. With numerous gene therapies currently in clinical trials and employing recombinant viruses, the landscape of retinal therapeutics is rapidly evolving. This trend emphasizes the increasing focus on personalized medicine and targeted treatments, positioning the market for substantial expansion as novel therapies increasingly gain regulatory approvals and reach patients in need.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2025-2031)

• Market Overview
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2025-2031)

• Market Overview
• Genetic
• Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2025-2031)

• Market Overview
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2025-2031)

• Market Overview
• Oral
• Topical
• Intravitreal
• Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2025-2031)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2031)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Size & CAGR (2025-2031)

• North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio, Inc. (USA) (Acquired by Astellas)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemera Biosciences (USA) (Acquired by Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gyroscope Therapeutics (UK) (Acquired by Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations